

Supplementary tables

Supplementary 1.a. Best supportive care costs and inflation adjustment

Best supportive care	Figure	Reference
1 month of BSC	£193	NICE TA405 ²⁰
Bank of England inflation multiplier	1.345	Bank of England inflation calculator ⁴¹
Total cost	£260	

Supplementary 1.b. Weighted unit cost of bevacizumab

	Usage level	Cost†	Percentage of total usage
Total 100 mg vial	¶¶	¶¶	¶¶
Avastin 100 mg	¶¶	¶¶	¶¶
Almysys 100 mg	¶¶	¶¶	¶¶
Oyavas 100mg	¶¶	¶¶	¶¶
Weighted average cost per 100 mg vial	¶¶	¶¶	¶¶
Total 400 mg vial	¶¶	¶¶	¶¶
Avastin 400 mg	¶¶	¶¶	¶¶
Almysys 400 mg	¶¶	¶¶	¶¶
Oyavas 400 mg	¶¶	¶¶	¶¶
Weighted average cost per 400 mg vial		¶¶	
*Usage in Wales from 1 Jan 2024 to 31 Dec 2024, taken from Medusa Cube.			
†Costs are All Wales contract prices.			
¶¶ commercial in confidence figure removed			

Supplementary 1.c. Crude weighted median duration for treatment with regorafenib.

Trial	Median duration of treatment (months)	N =	References
CORRECT	2.80	505	CORRECT ²⁹
CONCUR	2.40	136	CONCUR ²⁸
Weighted average	2.72		

Supplementary 1.d. Distribution of patients across lines of therapy.

Line of therapy and comparator in CCA as informed by clinical expert	Clinical expert: percentage of patients reaching each line of therapy	Midpoint figure	Distribution of patients who have reached 3rd line across subsequent lines.
3rd line: trifluridine-tipiracil + Bevacizumab	40-50%	45%	56.25%
4th line: Regorafenib	20-30%	25%	31.25%
5th line: BSC	10%	10%	12.50%

Supplementary 1.e. Clinical trial patient cohort alignment with delivery within NHS Wales.

Line of therapy and medication	Clinical trial cohort compared to line of therapy within NHS Wales
Intervention 3 rd line and later panitumumab	CHRONOS trial ² . The median prior treatments are 3 ranging from (2-6).
3 rd line: trifluridine-tipiracil + Bevacizumab	SUNLIGHT trial ²⁷ . Greater than 90% of the patient cohort received trifluridine-tipiracil + Bevacizumab in the third line.
4 th line: Regorafenib	CORRECT trial ²⁹ . 52% ≤ 3 prior lines of therapy for metastatic disease. CONCUR trial ²⁸ . 43% ≤ 3 prior lines of therapy for metastatic disease.

*Note: granularity of cohort reporting means that exact matching is often unknown, in cases where the distribution of the patient cohort matching the line is unknown the closest match is reported.

Supplementary 1.f: Quality of life score

QoL at baseline	QoL figure	N =	Reference
Panitumumab treatment arm Wild- type KRAS	0.73	112	Odom et al 2011 ³⁶
BSC alone comparator Wild- type KRAS	0.68	96	Odom et al 2011 ³⁶
Crude weighted QoL	0.71		